{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:34:27Z","timestamp":1791315267173,"version":"4.3.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.rmed.2025.108134","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:15:12Z","timestamp":1746058512000},"page":"108134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Short term exacerbation risk and exhaled nitric oxide in COPD"],"prefix":"10.1016","volume":"243","author":[{"given":"A.","family":"Romero- Linares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"\u00c1lvarez- Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hoyas- S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jim\u00e9nez- Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Almansa- L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Casares- Martin- Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"S\u00e1nchez- \u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Murillo- Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"G\u00f3mez- Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"G\u00f3mez- Pontes Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Romero- Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Alc\u00e1zar- Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2025.108134_bib1","article-title":"Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019","volume":"59","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.rmed.2025.108134_bib2","doi-asserted-by":"crossref","first-page":"00838","DOI":"10.1183\/23120541.00838-2023","article-title":"Global mortality and readmission rates following COPD exacerbation-related hospitalisation: a meta-analysis of 65 945 individual patients","volume":"10","author":"Waeijen-Smit","year":"2024","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.rmed.2025.108134_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101574","article-title":"Accept 2\u00b70: recalibrating and externally validating the Acute COPD exacerbation prediction tool (ACCEPT)","volume":"51","author":"Safari","year":"2022","journal-title":"EClinicalMed."},{"key":"10.1016\/j.rmed.2025.108134_bib4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(17)30217-5","article-title":"Eosinophils in COPD: just another biomarker?","volume":"5","author":"Bafadhel","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2025.108134_bib5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook","volume":"208","author":"Rabe","year":"2023","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.108134_bib6","article-title":"Type 2 inflammation in COPD: is it just asthma?","volume":"20","author":"Beech","year":"2024","journal-title":"Breathe (Sheff)"},{"key":"10.1016\/j.rmed.2025.108134_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00408-014-9591-8","article-title":"Exhaled nitric oxide predicts eosinophilic airway inflammation in COPD","volume":"192","author":"Chou","year":"2014","journal-title":"Lung"},{"key":"10.1016\/j.rmed.2025.108134_bib8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2147\/COPD.S44552","article-title":"Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study","volume":"9","author":"Donohue","year":"2014","journal-title":"Int. J. Chron. Obstruct. Pulmon Dis New Zealand"},{"key":"10.1016\/j.rmed.2025.108134_bib9","article-title":"Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD","volume":"51","author":"Alc\u00e1zar-Navarrete","year":"2018","journal-title":"European Respirat. J."},{"key":"10.1016\/j.rmed.2025.108134_bib10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.arbres.2018.02.006","article-title":"Alveolar and bronchial nitric oxide in chronic obstructive pulmonary disease and asthma-COPD overlap","volume":"54","author":"Alc\u00e1zar-Navarrete","year":"2018","journal-title":"Arch BronconeumoL"},{"key":"10.1016\/j.rmed.2025.108134_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.niox.2016.02.003","article-title":"Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes","volume":"54","author":"Alc\u00e1zar-Navarrete","year":"2016","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.rmed.2025.108134_bib12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arbres.2021.11.006","article-title":"T2 biomarkers as predictors of exacerbations of chronic obstructive pulmonary disease","volume":"58","author":"Alc\u00e1zar-Navarrete","year":"2022","journal-title":"Arch BronconeumoL."},{"key":"10.1016\/j.rmed.2025.108134_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00409-0","article-title":"Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials","author":"Bhatt","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2025.108134_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108134_bib15","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108134_bib16","series-title":"Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease Using Exhaled Nitric Oxide","author":"Dummer","year":"2008"},{"key":"10.1016\/j.rmed.2025.108134_bib17","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","year":"2005","journal-title":"Am. J. Respir Crit. Care Med. United States"},{"key":"10.1016\/j.rmed.2025.108134_bib18","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.108134_bib19","series-title":"Development and Validation of a New Comorbidity Index for COPD. European","author":"Divo","year":"2011"},{"key":"10.1016\/j.rmed.2025.108134_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021322","article-title":"The body mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease","volume":"350","author":"Celli","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108134_bib21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1440-1843.2010.01711.x","article-title":"Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations","volume":"15","author":"Antus","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.rmed.2025.108134_bib22","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","article-title":"Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial","volume":"29","author":"Siva","year":"2007","journal-title":"Eur. Respir. J. England"},{"key":"10.1016\/j.rmed.2025.108134_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: mechanism of action, clinical, and translational science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.rmed.2025.108134_bib24","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1007\/s10753-013-9653-8","article-title":"Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide","volume":"36","author":"Soter","year":"2013","journal-title":"Inflammation"},{"key":"10.1016\/j.rmed.2025.108134_bib25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.pupt.2008.04.006","article-title":"Exhaled nitric oxide monitoring in COPD using a portable analyzer","volume":"21","author":"de Laurentiis","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2025.108134_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12111906","article-title":"Fractional exhaled nitric oxide (FENO) in patients with stable chronic obstructive pulmonary disease: short-term variability and potential clinical implications","author":"Ambrosino","year":"2022","journal-title":"J. Pers. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125001969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125001969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T23:26:07Z","timestamp":1762039567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125001969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":26,"alternative-id":["S0954611125001969"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108134","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short term exacerbation risk and exhaled nitric oxide in COPD","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108134"}}